Revenue grew 1.0% year-over-year to 153.5 KRW bn, but operating profit fell 5.0% and net loss widened due to one-off US asset disposal costs. BTI showed strong growth, while NBT and Pharma underperformed. New sales and recovery are expected in key segments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.